EUCTR2021-003301-22-ES进行中（未招募）1 期
A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB(CONSTAN) - CONSTA
Archivel Farma S.L.0 个研究点目标入组 56 人开始时间: 2021年7月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, a patient must meet all of the following criteria:
- •1.Adults (females and males) aged = 18;
- •2.Written informed consent in a language they understand.
- •This includes informed consent to be in the trial and informed consent to collect specimens
- •3.Laboratory confirmed pulmonary TB (with or without extrapulmonary involvement) defined as a hard copy of a sputum laboratory result that reports Mtb detection by sputum-microscopy smear-positive at least 1+, rapid molecular assay or mycobacterial culture.
- •4.Patients who have not received any anti-tubercular treatment in the last 24 hours
- •5.Females of non-childbearing potential: at least 2 years post-menopausal or surgically sterile (e.g. tubal ligation);
- •6.Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrolment and must agree to use highly effective methods of birth control (i.e. diaphragm plus spermicide or male condom plus spermicide, oral contraceptive in combination with a second method, contraceptive implant, injectable contraceptive, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in the study;
- •7.Males must agree to use a double barrier method of contraception (condom plus spermicide or diaphragm plus spermicide) at least 1 month after RUTI/placebo vaccination; or the male patient or his female partner must be surgically sterile (e.g. vasectomy, tubal ligation) or the female partner must be post-menopausal;
- •8.The patient must be willing and able to attend all study visits and comply with all study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 56
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A potential patient who meets any of the following criteria will be excluded from participation in this study:
- •1.Unable to provide written informed consent;
- •2.Women reported, or detected, or willing to be pregnant during the trial period;
- •3.Severity of illness precluding full evaluation: expected early death, evidenced by respiratory failure, low blood pressure, WHO performance score 3-4
- •4.Bodyweight < 40kg
- •5.Evidence of rifampicin resistance via GeneXpert
- •6.Unstable Diabetes Mellitus as a poor metabolic control within the past 12 months
- •7.For HIV infected subjects if the CD4+ count <250 cells/?L
- •8.Major co-morbid conditions or any other finding which in the opinion of the investigator would compromise the protocol compliance or significantly influence the interpretation of results (i.e. cancer, immunodeficiency of any nature including treatment with immunosuppressant drugs and excluding HIV infection)
- •9.Any of the following laboratory parameters:
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
- •Total bilirubin > 2 x ULN
- •Neutrophil count = 500 neutrophils / mm3
- •Platelet count < 50,000 platelets / mm3
- •10.Alcohol use: potential participant either self-reports or in the investigator’s opinion that the patient drinks more than an average of four units/day over a usual week or is a binge drinker (men: 5 or more drinks; women: consume 4 or more drinks, in about 2 hours)
- •11.Documented allergy to TB vaccines or any of the study treatment excipients, notably, to the RUTI® vaccine
- •12.Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
研究者
相似试验
进行中（未招募）
2 期
A phase II study of M605106 for acne vulgarisJPRN-jRCT2031210011ishiura Tomoyuki240
招募中
2 期
A phase II trial to evaluate the efficacy and safety of Crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocationsAdenocarcinoma of the lung harbouring ROS1 translocationC34.9Bronchus or lung, unspecifiedDRKS00005409niversitätsklinikum Köln30
进行中（未招募）
1 期
FOLFIRI + panitimumab first-line treatment of metastatic colorectal cancer in elderly patients with good performance statusEUCTR2017-001639-38-ESGrupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
进行中（未招募）
不适用
A Phase 2b to investigate the effectiveness of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.Rheumatoid arthritisEUCTR2011-005634-19-CZMedImmune Ltd280
进行中（未招募）
不适用
A Phase 2b to investigate the effectiveness of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2011-005634-19-PLMedImmune Ltd280